论文部分内容阅读
目的:对比分析奈达铂联合多西他赛化疗方案和顺铂联合多西他赛化疗方案治疗中晚期非小细胞肺癌的疗效和不良反应。方法:73例中晚期非小细胞肺癌患者,其中37例采用奈达铂联合多西他赛治疗(试验组),36例采用顺铂联合多西他赛治疗(对照组)。结果:试验组有效率为32.43%,和对照组(36.11%)相比,无统计学差异(P>0.05);试验组胃肠道反应发生率明显低于对照组(P<0.01);两组肾脏毒性无明显差异(P>0.05);两组白细胞下降发生率分别为24.32%和25.00%(P>0.05);试验组血小板下降较对照组显著(48.65%vs27.78%,P<0.05)。结论:奈达铂联合多西他赛治疗中晚期非小细胞肺癌疗效不低于顺铂联合多西他赛,但胃肠道毒性显著减轻。
OBJECTIVE: To compare and analyze the efficacy and side effects of nedaplatin combined with docetaxel chemotherapy and cisplatin combined with docetaxel chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: Totally 73 patients with advanced non-small cell lung cancer were treated with nedaplatin combined with docetaxel (experimental group) and 36 with cisplatin combined with docetaxel (control group). Results: The effective rate of the experimental group was 32.43%, which was not significantly different from that of the control group (36.11%) (P> 0.05). The incidence of gastrointestinal reaction in the experimental group was significantly lower than that in the control group (P <0.01) (P> 0.05). The incidences of leukopenia in the two groups were 24.32% and 25.00%, respectively (P> 0.05). The platelet count in the experimental group was significantly lower than that in the control group (48.65% vs 27.78%, P <0.05) ). Conclusion: The efficacy of nedaplatin combined with docetaxel in the treatment of advanced non-small cell lung cancer is not lower than cisplatin combined with docetaxel, but the gastrointestinal toxicity was significantly reduced.